Cancer of the nasal cavity and paranasal sinuses.

Abstract:

:Sinonasal malignancies continue to have poor survival rates. Disease-related mortality is usually the result of disease recurrence and progression at the primary site despite aggressive therapy. Complete surgical excision with postoperative radiation therapy remains the standard of care for resectable lesions. Improved reconstructive techniques have increased our ability to aggressively clear locally advanced disease in this anatomically challenging region, while reducing associated functional and cosmetic morbidity. Intensive multimodality treatment regimens coupled with newer medical technology may ultimately improve the long-prevailing poor prognosis of these tumors.

authors

Maghami E,Kraus DH

doi

10.1586/14737140.4.3.411

keywords:

subject

Has Abstract

pub_date

2004-06-01 00:00:00

pages

411-24

issue

3

eissn

1473-7140

issn

1744-8328

pii

ERA040309

journal_volume

4

pub_type

杂志文章,评审
  • Determining treatment intensity in elderly patients with multiple myeloma.

    abstract:INTRODUCTION:In the majority of cases, multiple myeloma is a disease occurring in elderly patients. In the last decades, a major improvement in myeloma patients' outcome has been achieved with the introduction of several new drugs. However, this positive outcome was less likely to occur in elderly patients. Areas cover...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2018.1496823

    authors: Salvini M,D'Agostino M,Bonello F,Boccadoro M,Bringhen S

    更新日期:2018-09-01 00:00:00

  • Treatment options for early breast cancer in elderly women.

    abstract::In clinical practice, approximately 50% of new cases of breast cancer occur in women over the age of 65 years, although very few elderly women have been enrolled in the numerous randomized trials conducted so far. Notwithstanding less aggressive biologic features compared with younger patients, breast cancer impacts o...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.4.2.197

    authors: Basso U,Brunello A,Pogliani C,Monfardini S

    更新日期:2004-04-01 00:00:00

  • Monoclonal antibodies as an addition to current myeloma therapy strategies.

    abstract:INTRODUCTION:Immunotherapy has emerged as a major class in the therapeutic arsenal of multiple myeloma. Cell-based immunotherapy (CAR T-cells) and monoclonal antibody-based immunotherapy (naked monoclonal antibodies, antibody-drug conjugates, and bispecific T-cell engagers) are the two cornerstones of this novel approa...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1837627

    authors: Jullien M,Touzeau C,Moreau P

    更新日期:2020-10-26 00:00:00

  • Combining surgery and chemotherapy for invasive bladder cancer: current and future directions.

    abstract::More than 13,000 patients died from invasive bladder cancer in 2005 alone. Radical cystectomy is the most commonly prescribed treatment for patients with muscle-invasive bladder cancer, or for those with a nonmuscle-invasive disease that is refractory to intravesical therapy. Despite advances in surgical technique and...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.2.281

    authors: Amiel GE,Lerner SP

    更新日期:2006-02-01 00:00:00

  • Robotic-assisted radical prostatectomy in 2010.

    abstract::This article reviews the current status of robotic-assisted radical prostatectomy (RARP) with outcome analysis. The published English literature (PubMed) database was searched extensively for major publications and large series on RARP. The search was carried out over the preceding 3-year period. Selected series were ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.35

    authors: Singh I,Hemal AK

    更新日期:2010-05-01 00:00:00

  • A catalogue of treatment and technologies for malignant pleural mesothelioma.

    abstract::Malignant pleural mesothelioma is an aggressive fatal malignancy with a prognosis that has not significantly improved in the last decades. This review summarizes the current state of treatment and the various attempts that are made to improve overall survival for patients with malignant pleural mesothelioma. It also d...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2016.1162100

    authors: Schunselaar LM,Quispel-Janssen JM,Neefjes JJ,Baas P

    更新日期:2016-01-01 00:00:00

  • Use of angiotensin-converting enzyme inhibitors in the prophylaxis of anthracycline or trastuzumab-related cardiac dysfunction: preclinical and clinical considerations.

    abstract::Cardiac toxicity is one of the most important long-term toxicities experienced by cancer survivors so that survival rate due to anticancer therapy may be negatively affected due to cardiac complications. Thus, the search for novel methods to lower the incidence of treatment-related cardiotoxicity is a priority for all...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2015.1047766

    authors: Abdel-Rahman O,Alorabi M

    更新日期:2015-01-01 00:00:00

  • Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.

    abstract:INTRODUCTION:PI3K inhibitors are an important new therapeutic option for the treatment of relapsed and refractory B-cell lymphoid malignancies. Idelalisib is a PI3Kδ inhibitor that has been approved for the treatment of lymphoma and chronic lymphocytic leukemia in the relapsed/refractory setting, and several other PI3K...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2017.1285702

    authors: Greenwell IB,Flowers CR,Blum KA,Cohen JB

    更新日期:2017-03-01 00:00:00

  • Current, new and novel therapy for castration-resistant prostate cancer.

    abstract::Androgen deprivation therapy is the standard of care for the initial treatment of metastatic prostate cancer. However, the majority of these patients live long enough to experience disease progression despite castration. This scenario is defined as castration-resistant prostate cancer (CRPC) and has a poor outcome and...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2013.811154

    authors: Gaya JM,Ahallal Y,Sanchez-Salas R,Barret E,Rozet F,Galiano M,Macek P,Durand M,Cerruti J,Prapotnich D,Ropert S,Bennamoun M,Cathelineau X

    更新日期:2013-07-01 00:00:00

  • Transsphenoidal microsurgery: past, present and future.

    abstract::In this report, we first describe the history of transsphenoidal surgery. We further elaborate on three fundamental surgical anatomy principles of transsphenoidal surgery for pituitary adenomas. First, the pituitary gland and, therefore, pituitary adenomas are extra-arachnoid structures, therefore the operation should...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.9s.S75

    authors: Ciric IS,Zhao J

    更新日期:2006-09-01 00:00:00

  • Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013.

    abstract::The treatment of metastatic colorectal cancer has evolved greatly in the last 15 years, involving combined chemotherapy protocols and, in more recent times, new biologic agents. Clinical benefit from the use of targeted therapy with bevacizumab, aflibercept, cetuximab, panitumumab and regorafenib in the treatment of m...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2014.949678

    authors: Price TJ,Segelov E,Burge M,Haller DG,Tebbutt NC,Karapetis CS,Punt CJ,Pavlakis N,Arnold D,Gibbs P,Shapiro JD

    更新日期:2014-12-01 00:00:00

  • Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience.

    abstract:BACKGROUND:Chemotherapy-induced toxic liver injury is a relevant issue in the clinical management of patients affected with metastatic colorectal cancer (mCRC). This retrospective study evaluated patterns of liver toxicity in patients treated with FOLinic acid, Fluorouracil, IRInotecan (FOLFIRI)-based regimens. METHOD...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/14737140.2015.1061937

    authors: Vincenzi B,Imperatori M,Picardi A,Vespasiani Gentilucci U,Gallo P,Fausti V,Spalato Ceruso M,Santini D,Tonini G

    更新日期:2015-01-01 00:00:00

  • Lymph node dissection for bladder cancer: the issue of extent and feasibility in the minimally invasive era.

    abstract::Lymph node dissection in bladder cancer is an integral part of radical cystectomy. It allows for accurate staging of the patient and will, therefore, serve to dictate additional treatment and add prognostic information. The issue of what is an adequate lymphadenectomy as to the extent and boundaries of the operation, ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.147

    authors: Ghavamian R,Hakimi AA

    更新日期:2009-12-01 00:00:00

  • Molecular pathways and potential therapeutic targets in glioblastoma multiforme.

    abstract::Glioblastoma multiforme (GBM) is the most common primary brain malignancy. The current standard of therapy consists of surgical resection followed by concurrent chemoradiotherapy with temozolomide. Despite steady advances in all therapeutic modalities, clinical improvements have been slow and the prognosis remains poo...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2013.852472

    authors: Wardak Z,Choe KS

    更新日期:2013-11-01 00:00:00

  • Darbepoetin alfa: potential role in managing anemia in cancer patients.

    abstract::Anemia in cancer patients is frequent but often under-recognized and under-treated. This may be related to misconceptions about the impact of anemia on cancer patients and ill-defined guidelines for treatment, as well as the inadequacies of current therapy. Darbepoetin alfa, a novel erythropoiesis-stimulating protein ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2.4.377

    authors: Pirker R,Smith R

    更新日期:2002-08-01 00:00:00

  • Cancer-related cachexia and oxidative stress: beyond current therapeutic options.

    abstract::Cancer-related anorexia/cachexia syndrome is a complex phenomenon in which metabolic abnormalities, proinflammatory cytokines produced by the host immune system, circulating tumor-derived catabolic factors, decreased food intake and probably additional unknown factors all play different roles. This review examines the...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.3.3.381

    authors: Mantovani G,Macciò A,Madeddu C,Massa E

    更新日期:2003-06-01 00:00:00

  • Abdominal wall desmoid tumors associated with pregnancy: current concepts.

    abstract::The desmoid tumors (DTs) are unusual soft-tissue tumors that have a propensity for aggressive local growth and may develop during, or soon after pregnancy. Pregnancy-associated DTs are uncommon and optimal management of this tumor has yet to be defined. Currently, controversy centers on the timing of surgical resectio...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.98

    authors: Johner A,Tiwari P,Zetler P,Wiseman SM

    更新日期:2009-11-01 00:00:00

  • Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options.

    abstract:INTRODUCTION:Adrenocortical carcinoma (ACC) is a rare tumor characterized by poor prognosis in most cases. Moreover, in most cases ACC produces an excess of adrenal steroid hormones with relevant clinical consequences. Areas covered: After an extensive literature search, this narrative review addresses diagnostic manag...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2018.1510325

    authors: Puglisi S,Perotti P,Cosentini D,Roca E,Basile V,Berruti A,Terzolo M

    更新日期:2018-11-01 00:00:00

  • Current concepts and future strategies in the management of intracranial germinoma.

    abstract::Radiation therapy is the backbone in the management of intracranial germinoma. In localized disease chemotherapy followed by whole brain irradiation is the present standard providing cure rates in excess of 90%. Craniospinal irradiation alone in metastatic disease provides equally excellent outcome. Chemotherapy is ab...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2014.856268

    authors: Kortmann RD

    更新日期:2014-01-01 00:00:00

  • Antineoplastic therapy-induced pulmonary toxicity.

    abstract::Pulmonary complications of antineoplastic therapy are common and are an important cause of respiratory morbidity. The pulmonary toxicity should be taken into account in every patient with respiratory problems who is or has been treated with antineoplastic agents. The diagnosis of drug-induced pulmonary toxicity is com...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2013.817684

    authors: Sadowska AM,Specenier P,Germonpre P,Peeters M

    更新日期:2013-08-01 00:00:00

  • Biography: Dr Iain Frame, director of research, prostate cancer UK.

    abstract::Sophia Maprayil, Commissioning Editor for Expert Review of Anticancer Therapy, talks to Dr Iain Frame, Director of Research for Prostate Cancer UK. Iain is Prostate Cancer UK's first Director of Research, responsible for overseeing the development and implementation of the charity's ambitious new research strategy. He...

    journal_title:Expert review of anticancer therapy

    pub_type: 面试

    doi:10.1586/14737140.2014.974898

    authors: Frame I,Maprayil S

    更新日期:2014-11-01 00:00:00

  • Surgical management of pediatric brain tumors.

    abstract::Brain tumors are the most common cause of cancer-related death and the second most common form of cancer in pediatric patients. Many of these tumors are treated primarily with surgery, either alone or in combination with radiation or chemotherapy. Recent advances have lead to greater survival and decreased morbidities...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.12s.S61

    authors: Heuer GG,Jackson EM,Magge SN,Storm PB

    更新日期:2007-12-01 00:00:00

  • Emerging agents for the treatment of mantle cell lymphoma.

    abstract::The characterization of the mantle cell lymphoma (MCL) entity had a major impact on patient management and has played a profound role in improving therapy. Although the prognosis is improving in MCL, there is no definitive proof that the therapies currently available will lead to cure. Few randomized studies have been...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.12.99

    authors: Camara-Clayette V,Hermine O,Ribrag V

    更新日期:2012-09-01 00:00:00

  • Latest developments in limb-salvage surgery in osteosarcoma.

    abstract::Limb-salvage surgery plays a major role in the management of patients with osteosarcoma. As prognosis improves, reconstructive options have come under greater scrutiny with regard to their durability and functionality. The advent of computer navigation-guided reconstruction is discussed in detail, along with methods b...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.225

    authors: Mangat KS,Jeys LM,Carter SR

    更新日期:2011-02-01 00:00:00

  • Pembrolizumab for the treatment of gastric cancer.

    abstract:INTRODUCTION:Gastric cancer is one of a few gastrointestinal malignancies in which immunotherapy has shown meaningful activity. Pembrolizumab is the first and only immune checkpoint inhibitor to be FDA-approved in gastric cancer. Areas Covered: This review summarizes the current and emerging clinical evidence for immun...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2018.1526084

    authors: Kamath SD,Kalyan A,Benson AB 3rd

    更新日期:2018-12-01 00:00:00

  • Biomarkers for prostate cancer detection.

    abstract::Since its approval by the US FDA in 1986, prostate-specific antigen (PSA) has been employed to monitor men with a diagnosis of prostate cancer. In 1994, PSA was approved for use in prostate cancer screening and has been employed worldwide. However, due to the limited specificity of PSA for the disease, novel biomarker...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.168

    authors: Reed AB,Parekh DJ

    更新日期:2010-01-01 00:00:00

  • Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview.

    abstract::This review summarizes the safety of sorafenib, an oral multikinase inhibitor, focusing on the randomized, placebo-controlled, Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) in renal cell carcinoma, which formed the basis of the approval of sorafenib. Similar to other targeted agents, ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.9.1193

    authors: Hutson TE

    更新日期:2007-09-01 00:00:00

  • Serous tubal intraepithelial carcinoma (STIC) - clinical impact and management.

    abstract:INTRODUCTION:Serous tubal intraepithelial carcinoma (STIC) is most likely precursor lesion of the most part of high-grade serous pelvis carcinomas, carcinosarcoma and undifferentiated carcinoma with incidence of 0.6% to 7% in BRCA carriers or women with strong family history of breast or ovarian carcinoma. STIC is a pa...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2016.1247699

    authors: Weinberger V,Bednarikova M,Cibula D,Zikan M

    更新日期:2016-12-01 00:00:00

  • Neoadjuvant chemotherapy in invasive bladder cancer.

    abstract::The role of neoadjuvant chemotherapy in muscle-invasive bladder cancer has been clarified by recent randomized studies and meta-analyses, which all showed that cisplatin-based, combination chemotherapy offers a significant survival advantage. Preoperative chemotherapy results in downstaging in a significant percentage...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.5.6.993

    authors: Bamias A,Dimopoulos MA

    更新日期:2005-12-01 00:00:00

  • Squamous cell carcinoma of the vulva: a review of present management and future considerations.

    abstract:INTRODUCTION:Although a relatively uncommon disease, the treatment of vulvar cancer has changed considerably over the years and has been under considerable focus due to its past overtreatment and apparent increase in incidence. The purpose of this review is to describe the recommended management of the most commonly en...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2019.1538797

    authors: Buchanan T,Mutch D

    更新日期:2019-01-01 00:00:00